A Medical Device Daily
iCAD (Nashua, New Hampshire), a provider of computer-aided detection (CAD) solutions for the early identification of cancer, reported that two U.S. patents, No. 7,298,877 and No. 7,308,126, have recently been granted to the company by the U.S. Patent and Trademark Office (PTO).
“These patent grants demonstrate our on-going commitment to broadening and protecting our intellectual property, and represent an important addition to our portfolio of CAD product and technology patents,” said Ken Ferry, president/CEO of iCAD. “The first patent provides an information fusion method for multiple indicators of cancer by using a specific method of combining lesion information, while the second patent addresses improved clinical workflow.”
These patent awards bring the number of issued patents in 2007 to four, which includes two patents issued in June related to CAD billing workflow support and CAD for virtual colonoscopy.
iCAD also is developing solutions for use with virtual colonoscopy to improve the detection of colonic polyps based on algorithms that analyze the data, automatically identifying and marking suspicious regions in the images.
In other patent news:
• Micromem Technologies (Toronto) reported it has filed two new patent applications to enhance its portfolio of patents and applications directed to magnetic sensors and memory devices.
“It has been a very productive year for Micromem, having moved the company from the laboratory into a commercialization facility. The company’s strategy is to continuously enhance its patent portfolio which will enable the Company to negotiate partnerships from a position of strength,” said company spokesman Joseph Fuda.
Micromem Technologies develops magnetic random access memory technology.
•PuriCore (Malvern, Pennsylvania) said the PTO has granted PuriCore an additional patent for its Sterilox Systems. The new patent, U.S. patent No. 7,303,660, is part of the same patent family as PuriCore’s previously issued U.S. Patent No. 6,632,347, which covers an optimal process for operating PuriCore’s Systems to prepare its disinfection solutions.
PuriCore’s technology is marketed currently in the U.S. and U.K. as Sterilox Food Safety Systems and Sterilox Endoscopy Systems, respectively. These Sterilox Systems produce hypochlorous acid at near neutral pH, the same safe and effective antimicrobial solution produced by the human body to fight infection. U.S. supermarket retailers and UK hospitals use the systems to control the spread of infectious pathogens.